September 20, 2023 06:39 AM EDTUpdated September 25, 06:52 AM

Updated: Roche’s Genentech wades into radiopharmaceuticals with PeptiDream alliance, $40M upfront

Amber Tong

In one of its first forays into radiopharmaceuticals, Roche’s Genentech has lined up a discovery and development pact with the peptide specialists at PeptiDream. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Roche’s Genentech wades into radiopharmaceuticals with PeptiDream alliance, $40M upfront

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Roche’s Genentech wades into radiopharmaceuticals with PeptiDream alliance, $40M upfront